IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a ...

The post-marketing safety study showed that Xeljanz (tofacitinib) – used to treat rheumatoid arthritis (RA) – was associated with a higher rate of heart attacks and cancer than a TNF inhibitor ...

Xeljanz (tofacitinib) is approved at the higher dose of 10 mg twice daily in patients with ulcerative colitis, although this can be reduced to 5 mg twice daily in patients who respond well.

WASHINGTON -- Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA) may not have to worry so much about ...

She recommended that the patient start tofacitinib (Xeljanz, Pfizer) while continuing to receive vedolizumab every 4 weeks. In addition, she recommended that the patient have her calprotectin ...